SGHT
$3.89
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States.
Recent News
Sight Sciences, Inc. Q4 2025 Earnings Call Summary
Moby summary of Sight Sciences, Inc.'s Q4 2025 earnings call
Sight Sciences Inc (SGHT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ...
Sight Sciences Inc (SGHT) reports a 7% revenue increase and strategic focus on market access, despite cash reserve declines and reimbursement hurdles.
Sight Sciences Q4 Earnings Call Highlights
Sight Sciences (NASDAQ:SGHT) reported fourth-quarter 2025 results highlighting growth in both its interventional glaucoma and interventional dry eye segments, alongside what management described as continued operating expense discipline and cash management. The company also initiated 2026 revenue gu
Sight Sciences (SGHT) Q4 2025 Earnings Transcript
Also in attendance is Sight Sciences, Inc. Chief Operating Officer, Alison Bauerlein. Earlier today, Sight Sciences, Inc. released its financial results for the fourth quarter ended December 31, 2025, and initiated its revenue guidance and adjusted operating expense guidance for full year 2026.
Sight Sciences (SGHT) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.